Neogen Chemicals saw a significant 22% year-on-year increase in Q4 revenue to INR 247 crore, thanks to higher volume sales, optimal plant usage, and strategic moves such as expanding into lithium-ion battery materials. The company's EBITDA stood at INR 44 crore with a margin of 17.8%.

Neogen Chemicals commences trial production at their Dahej facility, marking a shift from commissioning to experimental and early-stage operation.

Neogen Chemicals anticipates increased revenues in the second half of FY27, thanks to imminent expansion of their production capabilities, indicating a promising outlook for future growth.

Neogen Chemicals is set to debut an electrolyte production facility by September 2026, a move aimed at increasing capacity and potentially boosting profit margins in the future.

Neogen Chemicals experienced a significant boost of 11%, reaching Rs 1,752.6, following the exclusion from the ASM framework. This surge can be attributed to an improvement in market sentiment and favorable feedback from SBICap Securities.

Neogen Chemicals, aiming to decrease India's reliance on Chinese imports for EV battery components, reported a 3.15% increase in share price at ₹1,718. The boost comes from their strategic move into lithium electrolyte salts production. Despite Q4 revenue growth of 21% YoY, margin compression to 18.2% occurred due to scaling challenges, with future capacity expansions planned by FY27.

Neogen Chemicals experienced an 8.1% dip today, closing at ₹1,556.55, despite a positive market trend. This decline may be attributed to some short-term unfavorable indicators affecting the stock's performance.

Neogen Chemicals reported a remarkable 209% surge in Q4 profits for FY26, amounting to ₹11.4 crore. However, the company's earnings are marred by margin pressures, high debt levels, and an annual stock increase of 9.7%, which have sparked concerns among investors.

Neogen Chemicals has recorded a 10.6% year-over-year increase in FY26 revenue, reaching ₹855.5 crore, with Q4 revenue jumping 22% compared to the previous quarter at ₹249 crore. However, cost overruns and delays are reported for Neogen Ionics subsidiary projects, causing a revised total capital expenditure of ₹1,795 crore and scheduled start of operations in 2027.

Neogen Chemicals' Q4 earnings show a remarkable 373% increase, marking a significant growth in their net profit for the fiscal year ending in March 2026.

Neogen Chemicals anticipates a transformative financial year 2027, thanks to the planned large-scale battery materials plant in Pakhajan. The company aims to amplify its electrolyte operations at Dahej and targets revenue between 8.75 and 9.5 billion Indian rupees.

Neogen Chemicals has reported a Q4 EBITDA increase of ₹453 million, marking a year-on-year growth from ₹413 million. However, the EBITDA margin saw a dip to 18.2% compared to last year's 20.3%.

Neogen Chemicals will review their financial year 2026 results and propose a final dividend on May 16, 2026. According to SEBI regulations, the trading window remains closed for 48 hours following the announcement of the results.

On May 8, 2026, Neogen Chemicals experienced a notable jump of 8.6%, reaching an intraday high of Rs 1862.05. This substantial surge in price reflects significant trading activity, with the stock demonstrating a high intraday volatility of 37.5%.

HDFC Securities has adjusted its portfolio, reducing exposure to automotive stocks while increasing investments in financials and chemicals. Head Varun Lohchab expresses concern about auto sector margins and recommends SRF, Neogen Chemicals, and Aether as potential investments instead.

Neogen Chemicals has greenlighted a ₹100 crore rights issue of 71 million shares for the development of lithium-ion battery materials, raising its capital to approximately ₹99 crores.

Neogen Chemicals has issued 10 million shares to Cadamba Solutions at ₹1610 apiece, generating approximately ₹161 crore in funds. Per SEBI guidelines, these shares will remain locked-in for a period of 18 months.

Axis Trustee Services has revealed that 7.65% of Neogen Chemicals shares are pledged under SEBI SAST regulations, totaling approximately 20.2 million shares. Despite the acquisition, the company's equity share capital remains at 2.64 million shares.

Neogen Chemicals held a virtual Extraordinary General Meeting on March 29th, 2026, concerning an equity issuance. The voting results for this proposed share offering are expected to be announced within the next 48 hours, which will then be made publicly available online.